FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib by Phil Taylor Friday, April 20, 2018 Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib may be scuppered again by FDA concerns on safety.
FDA moves the goal line on AbbVie's endometriosis med elagolix by Amirah Al Idrus Tuesday, April 10, 2018 The FDA will make its decision on AbbVie's elagolix to Q3, as it needs more time to review liver function tests.
As Sanofi buyout nears, Ablynx lupus drug flunks midphase trial by Nick Paul Taylor Monday, March 26, 2018 The setback tarnishes one of the drugs Sanofi is set to acquire through its €3.9 billion takeover of Ablynx.
AbbVie ditches plans for accelerated Rova-T review after weak phase 2 data by Ben Adams Thursday, March 22, 2018 AbbVie is abandoning plans to seek out an FDA quick OK for its troubled oncology drug Rova-T in third-line relapsed/refractory small cell lung cancer.
TAE bags $40M to take targeted radiotherapy mainstream by Nick Paul Taylor Monday, March 12, 2018 The startup, a spinout from a nuclear fusion company, wants to take BNCT out of nuclear research reactors and into hospitals.
AbbVie doubles down on tau with Voyager Alzheimer's deal by Phil Taylor Tuesday, February 20, 2018 AbbVie has teamed with Voyager Therapeutics on a tau protein-targeting program, paying $69 million for an option on the Alzheimer’s disease candidate.
New survival pathway unearthed in triple-negative breast cancer by Amirah Al Idrus Friday, February 9, 2018 A stem cell pathway could be targeted to create more effective treatments for triple-negative breast cancer.
Vertex picks drugs for mass-market cystic fibrosis combinations by Nick Paul Taylor Thursday, February 1, 2018 VX-659 and VX-445 landed spots in experimental triple combinations designed to treat 90% of cystic fibrosis patients.
Sanofi inks €3.9B Ablynx buyout to pip Novo in M&A fight by Nick Paul Taylor Monday, January 29, 2018 Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month.
Big biopharmas unite to sequence 500,000 exomes by Nick Paul Taylor Monday, January 8, 2018 The project will see Regeneron sequence the exomes of 500,000 Britons with the financial backing of AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer.
